Analyst Marc Goodman of Leerink Partners reiterated a Buy rating on Biohaven Ltd. (BHVN – Research Report), with a price target of $60.00.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Marc Goodman gave his rating based on several factors related to Biohaven Ltd.’s potential in addressing spinocerebellar ataxia (SCA). The company is on the brink of a significant milestone with the anticipated FDA decision regarding the New Drug Application (NDA) for troriluzole in SCA. This development follows positive data outcomes showing a 50-70% slowing in disease progression, as evidenced by real-world data from study BHV4157-206-RWE.
Goodman’s optimism is also fueled by the regulatory landscape, where there is a precedent for NDA approval in similar cases, combined with the high unmet medical need due to the lack of approved treatments for SCA. The stock’s previous positive reaction, a 20% increase, suggests investor confidence and a positive market outlook should the FDA accept the NDA. In such a scenario, Goodman anticipates further stock appreciation, while acknowledging the potential risk should the FDA issue a refusal to file. This risk-reward balance underpins his Buy rating.